echinocandins
Botanicalexperimental
Echinocandin B is a naturally occurring antibiotic, isolated from Aspergillus nidulans. It acts as an inhibitor of fungal β-1,3-glucan synthase thereby disrupting the formation of the fungal cell wall. The drug itself was not developed in the clinic, but instead, it was used in the production of other echinocandin derivatives. — NCATS
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
1
Earliest trial started Mar 1, 2012 (NCT01568489)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Beta-1,3-glucan synthaseINHIBITOR
CaFKS1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCC\C=C/C\C=C/CCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@@H](O)CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C4=CC=C(O)C=C4)[C@@H](C)O- Mol. weight
- 1060.2368 g/mol
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEchinocandin ↗
- NCATSCNW0ZW8ZTQ ↗
Also known as
- echinocandins
- hl-009
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06194201 | Phase 2 | Apr 27, 2024 | Jiangsu ShengDiYa Medicine Co., Ltd. |
| NCT02805049 | Phase 4 | Jan 1, 2017 | Centre Hospitalier Universitaire de Nīmes |
| NCT01568489 | Phase 2 | Mar 1, 2012 | HanAll BioPharma Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Centre Hospitalier Universitaire de Nīmes | Academic/Hospital | 1 | 1 | 1 | 2017 |
| HanAll BioPharma Co., Ltd. | For profit | 1 | 1 | 1 | 2012 |
| Jiangsu ShengDiYa Medicine Co., Ltd. | Government | 1 | 1 | 1 | 2024 |
3 organizations
Page 1 / 1